Excision BioTherapeutics

Focus: Excision BioTherapeutics is a gene-editing biotech company focused on developing curative therapies using gene therapy approaches. The company is publicly traded and operates from San Francisco as a mid-cap biotechnology firm.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Excision BioTherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Excision BioTherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EBT-101

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT05144386Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Phase 1

Help build intelligence for Excision BioTherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Gene editing is a high-growth, well-capitalized therapeutic area with significant investor interest and long-term commercial potential
Public company status provides liquidity, established infrastructure, and potential equity upside for early-stage career builders
Opportunity to work on curative modalities rather than symptomatic treatments, offering meaningful scientific impact

Watch Out For

Currently zero active job openings signals potential hiring freeze or organizational restructuring
Absence of disclosed pipeline data, clinical trials, or approved products indicates early-stage clinical progress with extended time to revenue

Generated by Claude from Excision BioTherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EBT-101

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT05143307Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2015

Portfolio: 2 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

2 pipeline

Marketed

Pipeline